

PROVIDER Update



CONTRACTUAL | SEPTEMBER 8, 2023 | UPDATE 23-1006 | 5 PAGES

Stay Current with the Injectable Medication HCPCS/DOFR Crosswalk Reference Table – 3rd Quarter 2023

Use the updates for dates of service on and after November 14, 2023

On July 11, 2023, the Health Net* Pharmacy and Therapeutics (P&T) Committee approved updates to the Injectable Medication Healthcare Common Procedure Coding System (HCPCS)/Division of Financial Responsibility (DOFR) Crosswalk.

The approved updates, effective November 14, 2023, are listed on pages 2-5 of this Provider Update. Injectable medications are placed in DOFR categories that mirror the DOFR matrix categories in the Health Net *Provider Participation Agreement (PPA)*.

The update includes:

- 17 new injectable medications to be added to the DOFR crosswalk.
- 26 updates and changes to injectable medication procedure codes.
- 20 updates for new generic drugs.

Additional information

Relevant sections of the Health Net's provider operations manuals have been revised to reflect the information contained in this update as applicable. Provider operations manuals are available electronically in the Provider Library after logging in to the provider portal at provider.healthnetcalifornia.com > *Provider Library* under Quick Links or go directly to providerlibrary.healthnetcalifornia.com.

If you have questions regarding the information contained in this update, contact the Provider Services Center by email at provider_services@healthnet.com, by phone or through the Health Net provider website as listed in the right-hand column.

Additions to injectable medication HCPCS/DOFR crosswalk

The following medications have been approved by the Health Net P&T Committee as additions to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table. P&T Committee members include physicians and representatives from participating physician groups (PPGs).

THIS UPDATE APPLIES TO:

- Participating Physician Groups

LINES OF BUSINESS:

- IFP
 - Ambetter HMO
 - Ambetter PPO
- Employer/Group
 - HMO/POS/HSP
 - EPO
 - PPO
- Wellcare By Health Net
 - Medicare Advantage (HMO)
 - Medicare Advantage (PPO)
- Medi-Cal
 - Kern
 - Los Angeles
 - Molina
 - Riverside
 - Sacramento
 - San Bernardino
 - San Diego
 - San Joaquin
 - Stanislaus
 - Tulare

PROVIDER SERVICES

provider_services@healthnet.com

Ambetter from Health Net IFP

Ambetter PPO – 844-463-8188

Ambetter HMO – 888-926-2164

Health Net Employer Group HMO, POS,

HSP, PPO, & EPO – 800-641-7761

Medicare (individual & employer group)

(Wellcare By Health Net) – 800-929-9224

Medi-Cal (including CS and ECM providers)

– 800-675-6110

PROVIDER PORTAL

provider.healthnetcalifornia.com

PROVIDER COMMUNICATIONS

provider.communications@healthnet.com

*Health Net of California, Inc., Health Net Community Solutions, Inc. and Health Net Life Insurance Company are subsidiaries of Health Net, LLC and Centene Corporation. Health Net is a registered service mark of Health Net, LLC. All other identified trademarks/service marks remain the property of their respective companies. All rights reserved.

CONFIDENTIALITY NOTE FOR FAX TRANSMISSION: This facsimile may contain confidential information. The information is intended only for the use of the individual or entity named above. If you are not the intended recipient, or the person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution, or use of the information contained in this transmission is strictly PROHIBITED. If you have received this transmission in error, please notify the sender immediately by phone or by return fax and destroy this transmission, along with any attachments. If you no longer wish to receive fax notices from Provider Communications, please email us at provider.communications@healthnet.com indicating the fax number(s) covered by your request. We will comply with your request within 30 days or less.

New drugs

HCPCS	Drug name	Generic name	Primary category	Secondary category
J0401	Abilify Asimtufii®	Aripiprazole intramuscular (IM) emergency suspension prefilled syringe	Therapeutic	
90678	Abrysvo™	Respiratory Syncytial Virus Vaccine solution for intramuscular injection	Therapeutic injection	Immunization
90679	Arexvy	Respiratory syncytial virus vaccine, adjuvanted	Therapeutic injection	Immunization
G2074	Brixadi™	Buprenorphine extended-release subcutaneous injection	Therapeutic injection	
J2249	Byfavo®	Injection, remimazolam, 1 mg	Therapeutic injection	
J3590	Elevidys	Delandistrogene moxeparvovec-rokl suspension, for intravenous infusion	Therapeutic injection	
J3590	Elfabrio®	Pegunigalsidase alfa-iwxj injection	Therapeutic injection	
J9999	Epkinly™	Epcoritamab-bysp injection for subcutaneous (SC) use.	Therapeutic injection	Chemotherapy ¹
J3590	Omisirge®	Omidubicel-ONLY Suspension for IV Infusion	Therapeutic injection	Chemotherapy ¹
J9177	Padcev®	Enfortumab vedotin-ejfv) for injection, for intravenous use	Therapeutic injection	Chemotherapy ¹
J3490	Qalsody™	Tofersen intrathecal solution 100 mg/15ml (6.7 mg/ml)	Therapeutic injection	
J3590	Rocktavian™	Valoctocogene roxaparvovec-rvox	Therapeutic injection	
J3590	Rystiggo®	Rozanolixizumab-noli injection, for subcutaneous use	Therapeutic injection	
J3490	Sogroya®	Somapacitan-beco injection, for subcutaneous use	Self-injectable	Growth hormone
J2356	Tezspire®	Tezepelumab-ekko injection, subcutaneous Solution auto-injector 210 mg/1.91ml national drug code (NDC) 55513-0123-01	Self-injectable	
J2356	Tezspire™	Tezepelumab-ekko injection, for syringe subcutaneous use NDC 55513-0112-01-intended for administration by a healthcare provider.	Therapeutic injection	
J3490	Uzedy™	Risperidone subcutaneous er susp prefilled syr 200 mg/0.56ml	Therapeutic injection	

Updates/changes to injectable medication procedure codes or medications

Updates to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table are based on changes or updates to HCPCS codes or changes in medication descriptions or availability. The following are changes to injectable medications currently listed in the crosswalk.

HCPCS	Drug name	Generic name	Comment
Q1256	Alymsys®	Bevacizumab-maly injection, for intravenous use	Replaces J3590
J2329	Briumvi™	Injection, ublituximab-xiiy, 1mg	Replaces J3590
J9029	Adstiladrin®	Nadofaragene firadenovec-vncg) suspension, for intravesical use	Replaces J3490
J9063	Elahere™	Injection, mirvetuximab soravtansine-gynx, 1 mg, for intravenous use	Replaces C9146
C9151	Empaveli™	Pegcetacoplan subcutaneous solution 1 mg	Replaces J3590
J2403	Iheezo™	Chloroprocaine HCl ophth gel 3%	Replaces J2400
J9347	Imjudo®	Tremelimumab-actl soln for IV infusion 25 mg/1.25ml	Replaces J9999
J7213	Ixinity®	Injection, coagulation factor IX (recombinant), Ixinity, 1 international unit (IU)	Replaces J7195
J9350	Lunsumio™	Injection, mosunetuzumab-axgb, 1 mg	Replaces J3590
J9371	Marqibo®	Vincristine sulfate liposome injection	No longer made
J1726	Makena®	Injection, hydroxyprogesterone caproate, 10 mg,	No longer made
J9297	Pemetrexed	Injection, pemetrexed (Sandoz) not therapeutically equivalent to J9305, 10 mg	Replaces J3590
J9322	Pemetrexed	Injection, pemetrexed (bluepoint) not therapeutically equivalent to J9305, 10 mg	Replaces J3590
J9294	Pemetrexed	Injection, pemetrexed (Hospira) not therapeutically equivalent to J9305, 10 mg	Replaces J3590
J9247	Pepaxto®	Melphalan flufenamide HCl for IV solution 20 mg	No longer manufactured
J1961	Sunlenca®	Injection, lenacapavir, 1 mg	Replaces J3490
J2561	Sezaby™	Injection, phenobarbital sodium (Sezaby), 1 mg	Replaces J3590
J1747	Spevigo®	Spesolimab-sbzo injection, for intravenous use	Replaces J3590
J9380	Tecvayli™	Injection, teclistamab-cqyv, 0.5 mg	Replaces C9148

Updates/changes to injectable medication procedure codes or medications, *continued*

HCPCS	Drug name	Generic name	Comment
90585	Tice® BCG 50 mg	Bacillus calmette-guerin vaccine (BCG) for tuberculosis, live, for percutaneous use	No longer manufactured
90586	Theracys® 81 MG/VIAL SUSR	Bacillus calmette-guerin vaccine (BCG) for bladder cancer, live, for intravesical use	No longer manufactured
J9030	Tice® BCG 50 mg	BCG (intravesical), per installation	Replaces J9031
J3315	Trelstar®	Triptorelin Pamoate for intramuscular (IM) suspension 3.75mg, 11.25mg, 22.5mg	Replaces J3316
J9381	Tzield™	Injection, teplizumab-mzwv, 5 mcg	Replaces J3590/C9149
J9056	Vivimusta™	Injection, bendamustine HCl, 1 mg	Replaces J3490
J1576	Panzyga®	Injection, immune globulin intravenous, non-lyophilized (e.g., liquid), 500 mg	Replaces J3590

New generic injectable medications

The following medications have been approved by the Health Net Pharmacy and Therapeutics Committee as additions to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table.

HCPCS	Drug name	Generic name	Primary category	Secondary category
J0216	Alfentanil	Alfentanil hydrochloride (HCl) injection	Therapeutic injection	
J0137	Acetaminophen	Injection, acetaminophen (Hikma) not therapeutically equivalent to J0131, 10 mg	Therapeutic injection	
J0206	Allopurinol	Injection, allopurinol sodium, 1 mg	Therapeutic injection	
J0457	Aztreonam	Injection, aztreonam, 100 mg	Therapeutic injection	Home Health/Infusion ²
J9058	Bendamustine	Injection, bendamustine HCl (Apotex), 1 mg	Therapeutic injection	Chemotherapy ¹
J9059	Bendamustine	Injection, bendamustine HCl (Baxter), 1 mg	Therapeutic injection	Chemotherapy ¹
J0665	Bupivacaine	Injection, bupivacaine, not otherwise specified, 0.5 mg	Therapeutic injection	
J0736	Clindamycin	Injection, clindamycin phosphate, 300 mg	Therapeutic injection	Home Health/Infusion ²

New generic injectable medications, *continued*

HCPCS	Drug name	Generic name	Primary category	Secondary category
J0737	Clindamycin	Injection, clindamycin phosphate (Baxter), not therapeutically equivalent to J0736, 300 mg	Therapeutic injection	Home Health/Infusion ²
J1805	Esmolol	Injection, esmolol HCl, 10 mg	Therapeutic injection	
J1806	Esmolol	Injection, esmolol HCl (WG Critical Care) not therapeutically equivalent to J1805, 10 mg	Therapeutic injection	
J1941	Furoscix	Injection, furosemide 20 mg	Therapeutic injection	
J1920	Labetalol	Injection, labetalol HCl, 5 mg	Therapeutic injection	
J1921	Labetalol	Injection, labetalol HCl (Hikma) not therapeutically equivalent to J1820, 5 mg	Therapeutic injection	
J1836	Metronidazole	Injection, metronidazole, 10 mg	Therapeutic injection	
J2305	Nitroglycerin	Injection, nitroglycerin, 5 mg	Therapeutic injection	
J9259	Paclitaxel	Injection, paclitaxel protein-bound particles (American Regent) not therapeutically equivalent to J9264, 1 mg	Therapeutic injection	Chemotherapy ¹
J2372	Phenylephrine	Injection, phenylephrine HCl (Biorphen), 20 mcg	Therapeutic injection	
J2599	Vasopressin	Injection, vasopressin (American Regent) not therapeutically equivalent to J2598, 1 unit	Therapeutic injection	
J2598	Vasopressin	Injection, vasopressin, 1 unit	Therapeutic injection	

HCPCS codes were taken from the Centers for Medicare & Medicaid Services HCPCS website at www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Alpha-Numeric-HCPCS.html.

¹If associated with a cancer diagnosis – ICD-10 codes between C00.0-C79.9, C7A.00-C7B.8, C80.0-C96.9, D00.0-D09.9.

²When administered by a nurse in a home setting.